
Foghorn Therapeutics FHTX
$ 5.18
3.6%
Annual report 2025
added 03-11-2026
Foghorn Therapeutics Total Non Current Liabilities 2011-2026 | FHTX
Annual Total Non Current Liabilities Foghorn Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 97.7 M | 78.9 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 97.7 M | 78.9 M | 88.3 M |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M | ||
|
Grifols, S.A.
GRFS
|
7.22 B | $ 7.72 | 1.85 % | $ 6.83 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
69.4 M | $ 19.68 | 0.92 % | $ 920 M | ||
|
Amarin Corporation plc
AMRN
|
31.7 M | $ 14.5 | 0.03 % | $ 6.02 B | ||
|
GlaxoSmithKline plc
GSK
|
37.5 B | $ 52.37 | 1.02 % | $ 173 B | ||
|
I-Mab
IMAB
|
131 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
184 M | - | 2.54 % | $ 160 B | ||
|
Ascendis Pharma A/S
ASND
|
101 M | $ 221.59 | -0.13 % | $ 5 B | ||
|
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M | ||
|
Autolus Therapeutics plc
AUTL
|
50.6 M | $ 1.39 | 1.46 % | $ 355 M | ||
|
Midatech Pharma plc
MTP
|
110 K | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
4.15 M | - | - | $ 26.5 M | ||
|
ARCA biopharma
ABIO
|
409 K | - | 1052.0 % | $ 415 M | ||
|
Aeterna Zentaris
AEZS
|
19.1 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
257 M | - | -24.86 % | $ 820 K | ||
|
Albireo Pharma
ALBO
|
79.1 M | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
4.59 M | - | 10.36 % | $ 9.8 M | ||
|
Acasti Pharma
ACST
|
12.2 M | - | 4.01 % | $ 150 M | ||
|
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - | ||
|
Heron Therapeutics
HRTX
|
14.6 M | $ 0.81 | 3.74 % | $ 135 M | ||
|
Avenue Therapeutics
ATXI
|
2.03 M | - | -52.27 % | $ 4.45 M | ||
|
Adverum Biotechnologies
ADVM
|
27.3 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
244 K | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
16 M | - | -9.65 % | $ 45.9 M | ||
|
Ayala Pharmaceuticals
AYLA
|
553 K | - | - | $ 7.46 M | ||
|
Benitec Biopharma
BNTC
|
213 K | $ 11.05 | 0.64 % | $ 455 M | ||
|
Atreca
BCEL
|
12.6 M | - | -11.76 % | $ 5.79 M | ||
|
BioDelivery Sciences International
BDSI
|
78.7 M | - | -4.8 % | $ 255 M | ||
|
BeiGene, Ltd.
BGNE
|
2 B | - | 0.49 % | $ 251 B | ||
|
Calithera Biosciences
CALA
|
4.82 M | - | -10.95 % | $ 876 K | ||
|
Cara Therapeutics
CARA
|
3.35 M | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
81.7 M | - | - | $ 3.74 B | ||
|
Bellerophon Therapeutics
BLPH
|
1.93 M | - | -74.18 % | $ 955 K | ||
|
Incyte Corporation
INCY
|
315 M | $ 90.36 | -0.47 % | $ 17.6 B | ||
|
InMed Pharmaceuticals
INM
|
338 K | $ 0.74 | -9.75 % | $ 1.81 M | ||
|
INmune Bio
INMB
|
126 K | $ 1.17 | -0.43 % | $ 21 M | ||
|
Checkpoint Therapeutics
CKPT
|
2.47 M | - | - | $ 169 M | ||
|
Clovis Oncology
CLVS
|
579 M | - | -7.23 % | $ 13 M | ||
|
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
112 M | - | - | $ 867 M | ||
|
Compugen Ltd.
CGEN
|
31.3 M | $ 2.13 | 1.91 % | $ 199 M | ||
|
Innate Pharma S.A.
IPHA
|
105 M | $ 1.35 | 15.38 % | $ 235 M | ||
|
Akero Therapeutics
AKRO
|
1.52 M | - | - | $ 3.67 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
25.6 M | $ 4.43 | 4.6 % | $ 735 M | ||
|
Inventiva S.A.
IVA
|
13.8 M | $ 6.1 | 5.5 % | $ 138 M | ||
|
Akouos
AKUS
|
12 M | - | 0.23 % | $ 488 M |